PreS1-Derived Peptide-Engineered Cell Membrane-Coated Nanoparticles Enhance Liver-Directed Curcumin Delivery in Acute Liver Injury
Pharmaceutics · 12.11.2026 · 18 (11) · 1470
DOI: 10.3390/pharmaceutics18111470 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 12.11.2026. Verfasst von Zhijie Hu und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Nanjing Special Fund for Health Science and Technology Development, National Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
Background
Liver injury remains a major clinical challenge, and the therapeutic performance of many candidate drugs is limited by poor bioavailability and insufficient tissue selectivity.
Methods
This study proposes a biomimetic delivery strategy based on genetically engineered cell membrane camouflage. Briefly, curcumin-loaded PLGA nanoparticles were co-ultrasonicated with genetically modified 293T cell membranes displaying a hepatocyte-binding peptide that originates from the preS1 region of the hepatitis B virus large surface protein, allowing the membrane-coated particles to self-assemble into a core–shell structure designated HBVP-MPNs, thereby achieving active hepatocyte-targeted delivery of curcumin. The resulting HBVP-MPNs were designed to engage sodium taurocholate cotransporting polypeptide (NTCP) and improve liver-directed delivery.
Results
HBVP-MPNs exhibited a mean particle diameter of approximately 197.9 nm, a core–shell morphology, high curcumin encapsulation efficiency, and slower cumulative curcumin release over 24 h than uncoated PNs (35.1% versus 51.6%). They showed approximately threefold higher cell-associated fluorescence in HepG2-NTCP cells and approximately 50% lower fluorescence in RAW264.7 macrophages than PNs in vitro. Following intravenous administration in mice, HBVP-MPNs displayed prolonged blood-associated fluorescence and increased liver accumulation. Upon therapeutic evaluation in a CCl₄-triggered murine model of acute hepatic injury, HBVP-MPNs elicited markedly lower circulating ALT and AST activities and conferred superior protection against histopathological abnormalities in liver tissue relative to free curcumin and non-targeted control formulations. Cytotoxicity, hemolysis, hematological, serum biochemical, and histological assessments indicated favorable tolerability within the present experimental settings.
Conclusions
Collectively, these data warrant further investigation of preS1 peptide-engineered cell membrane-coated nanoparticles as a biomimetic platform for liver-directed curcumin delivery in acute liver injury.
Förderung
- National Natural Science Foundation of China
- Nanjing Special Fund for Health Science and Technology Development
- National Science Foundation of Jiangsu Province
Zitieren
APA
Hu, Z., Chen, J., Jiang, Q., Han, H., Ding, W., & Zhang, Q. (2026). PreS1-Derived Peptide-Engineered Cell Membrane-Coated Nanoparticles Enhance Liver-Directed Curcumin Delivery in Acute Liver Injury. Pharmaceutics, 18(11), 1470. https://doi.org/10.3390/pharmaceutics18111470
Vancouver
Hu Z, Chen J, Jiang Q, Han H, Ding W, Zhang Q. PreS1-Derived Peptide-Engineered Cell Membrane-Coated Nanoparticles Enhance Liver-Directed Curcumin Delivery in Acute Liver Injury. Pharmaceutics. 2026;18(11):1470. doi:10.3390/pharmaceutics18111470
BibTeX
@article{Hu2026,
author = {Hu, Zhijie and Chen, Juan and Jiang, Qiuyue and Han, Haoyuan and Ding, Wanchuan and Zhang, Quan},
title = {PreS1-Derived Peptide-Engineered Cell Membrane-Coated Nanoparticles Enhance Liver-Directed Curcumin Delivery in Acute Liver Injury},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {11},
pages = {1470},
doi = {10.3390/pharmaceutics18111470}
}
EUVIMED